Jeena Sikho Q4 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 1
Margin
Category 1
Fundraise
N/A
Order
Yes
Capex
Yes
4 of 4 growth signals are positive — a strong management growth story.
Full analysisRevenue guidance
Category 1- Targeting 55% occupancy in FY '25, leading to revenue of around INR 450 crores.
- Planning to add 500 new hospital beds by March 2025, with incremental revenue expected from these additions.
- Revenue expected to reach INR 600-650 crores by FY '26 with 85% occupancy on older beds and 35% on 500 new beds.
- PAT margin projected to exceed 25% due to controlled expenses despite expansion.
- Medicine vertical grew by 32% YoY, with plans to launch 10 OTC patented formulas priced between INR 150-600.
- Focus on increasing patient awareness about cashless health insurance since April 2024, aiding revenue growth.
- Long-term plan to have 3,000 beds in 3 years and over 4,000 beds in 5 years, aiming to become India’s number one Ayurvedic healthcare company.
- Expanding in new segments such as infertility, heart, and liver diseases.
- International expansion underway with plans for centers in Mauritius and approvals in 112 countries.
See what Jeena Sikho management said on margin guidance — free account, 30 seconds.
Fundraise plans
- Manish Grover mentioned a budget of around INR 7.75 crores for adding a 300-bed hospital in Meerut, Chandigarh, Rajpura.
- For adding 500 beds over the next 2-3 years, total capex is estimated between INR 15 to 20 crores.
- The company primarily takes hospitals on rent and only invests in interiors, reducing upfront capex burden.
- There is no explicit mention of new fundraising through debt or equity in the discussed transcript.
- The expansion and capex appear to be managed through operational cash flows or owner contributions rather than new fundraising.
- The company plans to increase bed capacity by 500-600 beds every year over the next 5 years, indicating ongoing capital requirements, but no direct fundraising announcements.
See what Jeena Sikho management said on order book — free account, 30 seconds.
Capex plans
Yes- Planned addition of 500 new beds by FY2025, with capex of approximately INR3 lakh per bed (INR15 crores to INR20 crores for 500 beds).
- Specific hospital investments include 300 beds in Meerut, Chandigarh, Rajpura with a budget of around INR7.75 to 9 crores.
- Continued focus on adding 500-600 beds every year for the next 3-5 years, aiming to reach 3,000 beds in 3 years and above 4,000 beds in 5 years.
- New hospitals planned in Uttar Pradesh (Meerut - 350 beds, Lucknow - 100 beds, plus Kanpur, Agra, Banaras, Saharanpur, and potential hospital in Noida).
- Capex spent in FY24 was INR80 crores.
- No direct ownership of hospitals; properties are taken on rent with capex focused primarily on interiors.
- Strategic emphasis on NABH accreditation and cashless treatment integration in Ayurveda.
- Expansion plans include entering international markets like Mauritius, Dubai, and Canada with clinics/hospitals.
Track Jeena Sikho — get its next earnings analysis in your feed
Margin guidance
Category 1- Target revenue for FY25 is around INR 450 crores with a PAT margin of approximately 25%.
- Occupancy increase from current 37% to 55% expected to drive 50% growth in profit; potential to triple profit if occupancy reaches 80%.
- Plans to add 500 new beds by March 2025, with some beds operational mid-year, enhancing revenue and profit.
- Long-term target to scale to 3,000 beds in 3 years and over 4,000 beds in 5 years, supporting sustained growth.
- EBITDA and profit margins are improving, with FY24 showing 29% EBITDA margin and 21% PAT margin.
- Profit has grown faster than revenue, e.g., profit grew 3.75 times from 2022 to 2023 while revenue doubled.
- Expansion facilitated by government backing, increased insurance cashless benefits, and strong product portfolio growth.
Order book
Yes- The transcript does not explicitly mention current or expected order book or pending orders in numeric terms.
- However, Manish Grover discussed a robust expansion plan including adding 500 new beds by March 2025, increasing total beds from around 1,300 to 1,800.
- He also mentioned plans to open 15 new hospitals within the year, focusing on areas with higher patient inquiries and government healthcare plans.
- OTC medicine launches are planned within 3 to 6 months after market surveys, targeting chronic diseases with potentially large patient bases.
- The company is aiming to increase hospital occupancy from 37% to 55% in FY25, which would significantly boost revenues.
- Government support includes cashless health insurance starting April 2024, expected to improve patient inflow and order flow.
- Overall, the business pipeline looks strong with ongoing capacity additions and product launches, implying a growing order inflow though exact order book numbers are not disclosed.
How does Jeena Sikho rank vs peers in Leisure Services?
Pro featureHow does Jeena Sikho rank in Leisure Services?
Compare Jeena Sikho against every Leisure Services company (Q4 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Jeena Sikho's management said in earlier quarters
Others in Leisure Services this season
- Sapphire Foods (Q1 FY27)
Overall, consolidated revenue grew 15% in Q1 FY ‘27, the best in 11 quarters, with 37% adjusted EBITDA growth. Key concall takeaways from Sapphire Foods India…
- SPECIALITY (Q1 FY27)
Delivery business has grown to 29% of total revenue, complementing dine-in growth, driven by increased consumption occasions and digital-first brands like…
- Royal Orch.Hotel (Q1 FY27)
Consolidated revenue grew 38.5% in Q1 FY27, driven by new openings and existing portfolio growth. Key concall takeaways from Royal Orchid Hotels Ltd's Q1 FY27…
- Apeejay Surrend. (Q1 FY27)
70-80 crores cash flow this year, Rs. Key concall takeaways from Apeejay Surrendra Park Hotels Ltd's Q1 FY27 earnings call — and how it ranks against sector…